Log in

Millendo Therapeutics Stock Forecast, Price & News

-0.11 (-6.79 %)
(As of 10/27/2020 12:00 AM ET)
Today's Range
Now: $1.51
50-Day Range
MA: $1.63
52-Week Range
Now: $1.51
Volume739,152 shs
Average Volume791,666 shs
Market Capitalization$28.69 million
P/E RatioN/A
Dividend YieldN/A
Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.59 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:MLND



Sales & Book Value

Annual Sales$290,000.00
Book Value$3.28 per share


Net Income$-44,570,000.00


Market Cap$28.69 million
Next Earnings Date11/11/2020 (Estimated)
OptionableNot Optionable
-0.11 (-6.79 %)
(As of 10/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MLND News and Ratings via Email

Sign-up to receive the latest news and ratings for MLND and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Millendo Therapeutics (NASDAQ:MLND) Frequently Asked Questions

How has Millendo Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Millendo Therapeutics' stock was trading at $6.58 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MLND stock has decreased by 77.1% and is now trading at $1.51.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Millendo Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Millendo Therapeutics in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Millendo Therapeutics

When is Millendo Therapeutics' next earnings date?

Millendo Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for Millendo Therapeutics

How were Millendo Therapeutics' earnings last quarter?

Millendo Therapeutics, Inc. (NASDAQ:MLND) issued its quarterly earnings data on Monday, August, 10th. The company reported ($0.56) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.55) by $0.01.
View Millendo Therapeutics' earnings history

What price target have analysts set for MLND?

5 brokers have issued 12 month target prices for Millendo Therapeutics' stock. Their forecasts range from $2.00 to $6.00. On average, they anticipate Millendo Therapeutics' share price to reach $4.40 in the next twelve months. This suggests a possible upside of 191.4% from the stock's current price.
View analysts' price targets for Millendo Therapeutics

Are investors shorting Millendo Therapeutics?

Millendo Therapeutics saw a increase in short interest in October. As of October 15th, there was short interest totaling 955,500 shares, an increase of 39.2% from the September 30th total of 686,400 shares. Based on an average daily trading volume, of 419,300 shares, the short-interest ratio is presently 2.3 days.
View Millendo Therapeutics' Short Interest

Who are some of Millendo Therapeutics' key competitors?

What other stocks do shareholders of Millendo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Millendo Therapeutics investors own include Allena Pharmaceuticals (ALNA), Matinas BioPharma (MTNB), VYNE Therapeutics (VYNE), Acasti Pharma (ACST), Onconova Therapeutics (ONTX), TherapeuticsMD (TXMD), BioNano Genomics (BNGO), DURECT (DRRX), Geron (GERN) and Heat Biologics (HTBX).

Who are Millendo Therapeutics' key executives?

Millendo Therapeutics' management team includes the following people:
  • Dr. Julia C. Owens Ph.D., CEO, Pres & Director (Age 47, Pay $702.8k)
  • Mr. Louis J. Arcudi III, M.B.A., MBA, Chief Financial Officer (Age 59, Pay $495.79k)
  • Dr. Ryan Zeidan Ph.D., Chief Devel. Officer (Age 40, Pay $511.69k)
  • Ms. Tamara Lynn Joseph, Chief Legal Officer & Corp. Sec. (Age 57)
  • Mr. Thomas Hoover, Chief Bus. Officer
  • Dr. Christophe Arbet-Engels M.B.A., M.D., Ph.D., MBA, Chief Medical Officer (Age 58)

What is Millendo Therapeutics' stock symbol?

Millendo Therapeutics trades on the NASDAQ under the ticker symbol "MLND."

How do I buy shares of Millendo Therapeutics?

Shares of MLND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Millendo Therapeutics' stock price today?

One share of MLND stock can currently be purchased for approximately $1.51.

How big of a company is Millendo Therapeutics?

Millendo Therapeutics has a market capitalization of $28.69 million and generates $290,000.00 in revenue each year. The company earns $-44,570,000.00 in net income (profit) each year or ($3.25) on an earnings per share basis. Millendo Therapeutics employs 37 workers across the globe.

What is Millendo Therapeutics' official website?

The official website for Millendo Therapeutics is www.millendo.com.

How can I contact Millendo Therapeutics?

Millendo Therapeutics' mailing address is 110 MILLER AVENUE SUITE 100, ANN ARBOR MI, 48104. The company can be reached via phone at 734-845-9000 or via email at [email protected]

This page was last updated on 10/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.